Literature DB >> 14695674

Comparison of the seroprevalence of human metapneumovirus and human respiratory syncytial virus.

Takashi Ebihara1, Rika Endo, Hideaki Kikuta, Nobuhisa Ishiguro, Hiroaki Ishiko, Kunihiko Kobayashi.   

Abstract

Human metapneumovirus (hMPV) is a virus that induces human respiratory syncytial virus (hRSV)-like illnesses, ranging from upper respiratory tract infection to severe bronchiolitis and pneumonia. The 100 serum samples from children aged 1 month to 5 years were tested for the presence of hMPV and hRSV antibodies using an indirect immunofluorescence assay and a neutralizing-antibody assay, respectively. The seroprevalence of hMPV was significantly lower than that of hRSV in children over 4-months-old (43% vs. 60%, P < 0.025), and the difference was particularly notable between the ages of 4 months and 1 year (11% vs. 48%, P = 0.006). The results suggest that primary infection with hMPV occurs somewhat later than that with hRSV. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14695674     DOI: 10.1002/jmv.10572

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  24 in total

Review 1.  New Approaches for Immunization and Therapy against Human Metapneumovirus.

Authors:  Sherry C Wen; John V Williams
Journal:  Clin Vaccine Immunol       Date:  2015-06-10

2.  Experimental infection of adults with recombinant wild-type human metapneumovirus.

Authors:  Kawsar R Talaat; Ruth A Karron; Bhagvanji Thumar; Bridget A McMahon; Alexander C Schmidt; Peter L Collins; Ursula J Buchholz
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

3.  Characterization of human metapneumovirus infections in Israel.

Authors:  Liora Regev; Musa Hindiyeh; Lester M Shulman; Asher Barak; Virginia Levy; Roberto Azar; Yael Shalev; Zehava Grossman; Ella Mendelson
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

4.  Human metapneumovirus infections cause similar symptoms and clinical severity as respiratory syncytial virus infections.

Authors:  Anja Wilkesmann; Oliver Schildgen; Anna Maria Eis-Hübinger; Tilman Geikowski; Thomas Glatzel; Michael J Lentze; Udo Bode; Arne Simon
Journal:  Eur J Pediatr       Date:  2006-03-23       Impact factor: 3.183

Review 5.  Human Metapneumovirus: lessons learned over the first decade.

Authors:  Verena Schildgen; Bernadette van den Hoogen; Ron Fouchier; Ralph A Tripp; Rene Alvarez; Catherine Manoha; John Williams; Oliver Schildgen
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

6.  Population-based incidence of human metapneumovirus infection among hospitalized children.

Authors:  John V Williams; Kathryn M Edwards; Geoffrey A Weinberg; Marie R Griffin; Caroline B Hall; Yuwei Zhu; Peter G Szilagyi; Chiaoyin K Wang; Chin-Fen Yang; David Silva; Dan Ye; Richard R Spaete; James E Crowe
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

7.  Human coronavirus NL63 and 229E seroconversion in children.

Authors:  Ronald Dijkman; Maarten F Jebbink; Nawal Bahia El Idrissi; Krzysztof Pyrc; Marcel A Müller; Taco W Kuijpers; Hans L Zaaijer; Lia van der Hoek
Journal:  J Clin Microbiol       Date:  2008-05-21       Impact factor: 5.948

8.  High seroprevalence of neutralizing capacity against human metapneumovirus in all age groups studied in Bonn, Germany.

Authors:  Jessica Lüsebrink; Christoph Wiese; Anne Thiel; Ramona-Liza Tillmann; Vanessa Ditt; Andreas Müller; Oliver Schildgen; Verena Schildgen
Journal:  Clin Vaccine Immunol       Date:  2009-12-30

9.  Nutritional status, breastfeeding, and evolution of Infants with acute viral bronchiolitis.

Authors:  Cristina T L Dornelles; Jefferson P Piva; Paulo J C Marostica
Journal:  J Health Popul Nutr       Date:  2007-09       Impact factor: 2.000

10.  The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya.

Authors:  Rachel Ochola; Charles Sande; Gregory Fegan; Paul D Scott; Graham F Medley; Patricia A Cane; D James Nokes
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.